Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8886347 | 0.93 | TRPA1 (0.52) | TRPA1CES2CES1DPP4TSHR | |
| SCHEMBL11202378 | 0.77 | PTGS1 (0.53) | TRPA1TSHRCYP2D6ALDH1A1 | |
| Bromo Benzyl Cyanide SCHEMBL27315132 | 0.74 | TRPA1 (1.00) | TRPA1CES2CES1DPP4TSHR | |
| Bromo Benzyl Cyanide SCHEMBL437646 | 0.74 | TRPA1 (1.00) | TRPA1CES2CES1DPP4TSHR | |
| SCHEMBL1253893 | 0.74 | CES2 (0.41) | TRPA1CES2CES1DPP4TSHR | |
| SCHEMBL11795261 | 0.74 | TRPA1 (0.58) | TRPA1CES2CES1DPP4TSHR | |
| SCHEMBL5665560 | 0.74 | TRPA1 (0.58) | TRPA1CES2CES1DPP4TSHR | |
| SCHEMBL10640501 | 0.74 | TRPA1 (0.58) | TRPA1CES2CES1DPP4TSHR | |
| SCHEMBL27977481 | 0.73 | ACHE (0.42) | TRPA1TAAR1ALDH1A1 | |
| SCHEMBL11663962 | 0.72 | DPP4 (0.41) | TRPA1DPP4TSHRF2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534664-A1 | N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-ALPHA-HYDROXY-AND ALPHA-ALKOXY ACID AMIDES | Syngenta Participations AG (CH) | 2005-06-01 | — | — | EP | claimed |
| WO-2004011417-A1 | N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-ALPHA-HYDROXY-AND ALPHA-ALKOXY ACID AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-02-05 | — | — | WO | claimed |
| CN-117924773-A | Amorphous polymer film with high thermal stability and preparation method and application thereof | 浙江理工大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-101456836-A | Method for preparing 4-propargyl nitrogen heterocyclic butyl-2-one and 4-allenyl nitrogen heterocyclic butyl-2-one | SHANGHAI INST ORGANIC CHEM (CN) | 2009-06-17 | — | — | CN | disclosed |
| US-20090042888-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A | 2009-02-12 | — | — | US | disclosed |
| US-7115591-B2 | Pyridazinone compounds as cyclooxygenase [COX] 2 inhibitorsfor gastrointestinal disorders | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-7001895-B2 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | ABBOTT LABORATORIES (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1534664-A1 | N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-ALPHA-HYDROXY-AND ALPHA-ALKOXY ACID AMIDES | Syngenta Participations AG (CH) | 2005-06-01 | — | — | EP | disclosed |
| CN-1167687-C | Arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors | ���Ͽع�����˾ | 2004-09-22 | — | — | CN | disclosed |
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2004-08-12 | — | — | US | disclosed |
| WO-2004011417-A1 | N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-ALPHA-HYDROXY-AND ALPHA-ALKOXY ACID AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-02-05 | — | — | WO | disclosed |
| EP-0375452-A2 | Cycloalkane derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
| US-4933325-A | ANALGESICS, HYPOTENSIVE AGENTS | G. D. SEARLE & CO. (US) | 1990-06-12 | — | — | US | disclosed |
| US-4880829-A | ANALGESICS, HYPOTENSIVE AGENTS | G. D. SEARLE AND COMPANY (US) | 1989-11-14 | — | — | US | disclosed |
| US-4847241-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1989-07-11 | — | — | US | disclosed |
| US-4822775-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1989-04-18 | — | — | US | disclosed |
| EP-0215297-A2 | Substituted dipeptide amides | G.D. Searle & Co. (US) | 1987-03-25 | — | — | EP | disclosed |
| EP-0010297-B1 | DERIVATIVES OF POLYENE MACROLIDE ANTIBIOTICS CONTAINING AN AMINO SUGAR MOIETY, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1983-04-13 | — | — | EP | disclosed |
| US-4272525-A | FUNGICIDES | SCHERING CORPORATION (US) | 1981-06-09 | — | — | US | disclosed |
| EP-0010297-A1 | Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | TRPA1 1381/4885CES2 2785/4885CES1 327/4885 |
| US-20090042888-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGIS, PTGS1, PTGS2 | TRPA1 1185/4885CES2 2656/4885CES1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.